1. Honored Guest (Member ofEditorial Board)
Prof. Wilbert S. Aronow (New York Medical College, USA)
Prof. Sai Yendamuri (Roswell Park Cancer Institute, USA)
Honored Guest (Guest Editor)
Dr. Oscar Arrieta (Instituto Nacional de Cancerología (INCan), Mexico); Issue: Thoracic Oncology
Dr. Po-KueiHsu (Taipei-Veterans General Hospital, Taiwan); Issue: Esophageal Cancer
Honored Guests (Comments,Perspectivesor Editorials)
(Published)
1. Guest: Prof. Sabina Antoniu, Department of Preventive Medicine Interdisciplinary, Medicine-Palliative Care
Nursing, University of Medicine and Pharmacy, “Gr.T.Popa” Iasi, Romania
Title: Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout
Comment on: Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous
Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373:1627-39.
2. Prof. Ramon Andrade de Mello, 1Department of Biomedical Sciences and Medicine, University of Algarve,
Faro, Portugal; 2School of Medicine, University of Porto, Porto, Portugal; 3Clinical Research Center, Hospital
Haroldo Juaçaba, Instituto do Câncer do Ceará (ICC), Fortaleza, Brazil
Title: TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?
Comment on: Quoix E, Lena H, Losonczy G, et al. TG4010 immunotherapy and first-line chemotherapy for
advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind,
placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016 Feb;17:212-23.
3. Prof. Hiroyuki Suzuki, Department of Regenerative Surgery, Fukushima Medical University, 1-Hikarigaoka,
Fukushima, Japan
Title: Revisiting of cancer vaccine?-Specific immunotherapy comes to field with the biomarker
Comment on: Quoix E, Lena H, Losonczy G, et al. TG4010 immunotherapy and first-line chemotherapy for
advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind,
placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016 Feb;17:212-23.
4. Prof. Roy M. Bremnes, 1Institute of Clinical Medicine, The Arctic University of Norway; 2Department of
Oncology, University Hospital of Northern Norway, Tromsø, Norway
Title: Importance of tumor infiltrating lymphocytes in non-small cell lung cancer?
Comment on: Brambilla E, Le Teuff G, Marguet S, et al. Prognostic Effect of Tumor Lymphocytic Infiltration
in Resectable Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Apr 10;34:1223-30.
5. Dr. Fabrice Barlesi, Multidisciplinary Oncology & Therapeutic Innovations Department, Assistance Publique
Hôpitaux de Marseille, Aix Marseille University, Marseille, France
Title: Elderly selection on geriatric index assessment

2. Comment on: Corre R, Greillier L, Le Caër H, et al. Use of a Comprehensive Geriatric Assessment forthe
Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized
ESOGIA-GFPC-GECP 08-02 Study. J Clin Oncol. 2016 May 1;34(13):1476-83.
6. Prof. Apar Kishor Ganti, Division of Oncology-Hematology, Department of Internal Medicine, VA Nebraska
Western Iowa Health Care System, University of Nebraska Medical Center, Omaha, USA
Title: Resected small cell lung cancer-what do we do next?
Comment on: Yang CF, Chan DY, Speicher PJ, et al. Role of Adjuvant Therapy in a Population-Based Cohort
of Patients With Early-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016 Apr 1;34:1057-64.
7. Dr. Firdaus Mohamed Hoesein, Department of Radiology, University Medical Center Utrecht, Utrecht, The
Netherlands
Title: Personalized lung cancer screening: the value of spirometry and emphysema as risk modifiers
Comment on: Wille MM, Dirksen A, AshrafH, et al. Results of the Randomized Danish Lung Cancer Screening
Trial with Focus on High-Risk Profiling. Am J Respir Crit Care Med. 2016 Mar 1;193:542-51.
8. Dr. Wilbert S. Aronow, 1Division of Pulmonary, Critical Care, and Sleep Medicine, 2Division of Cardiology,
Department of Medicine, WestchesterMedicalCenter/New York Medical College, NY, USA
Title: Autofluorescence bronchoscopy forlung cancer screening: a time to reflect
Comment on: Tremblay A, Taghizadeh N, McWilliams AM, et al; Pan-Canadian Early Lung Cancer Study
Group.. Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of
Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study. Chest. 2016 Nov;150:1015-1022.
9. Dr. Fausto Petrelli, ASST Bergamo Ovest, Medical Oncology Unit, Treviglio, Italy
Title: Preventing or treating anti-EGFR related skin rash with antibiotics?
Comment on: Melosky B, Anderson H, Burkes RL, et al. Pan Canadian Rash Trial: A Randomized Phase III
Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-
Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. J Clin Oncol. 2016
Mar 10;34:810-5.
10. Dr. Oscar Arrieta, Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City,
Mexico
Title: Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth
factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial)
Comment on: Melosky B, Anderson H, Burkes RL, et al. Pan Canadian Rash Trial: A Randomized Phase III
Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-
Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. J Clin Oncol. 2016
Mar 10;34:810-5.
11. Prof. Chia-Yu Chu, Department of Dermatology, National Taiwan University Hospital and National Taiwan
University College of Medicine, Taipei, Taiwan
Title: Treatment strategies of epidermal growth factor receptor inhibitor-induced skin toxicities: pre-emptive or
reactive?

3. Comment on: Melosky B, Anderson H, Burkes RL, et al. Pan Canadian Rash Trial: A Randomized Phase III
Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-
Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. J Clin Oncol. 2016
Mar 10;34:810-5.
12. Dr. Paolo Navalesi, 1Anesthesia and Intensive Care, Sant’Andrea Hospital, Vercelli; 2Department of
Translational Medicine, Eastern Piedmont University “A. Avogadro”, Novara; 3CRRF Mons. L. Novarese,
Moncrivello, Italy
Title: Non-invasive ventilation in hypoxemic patients: does the interface make a difference?
Comment on: Patel BK, Wolfe KS, Pohlman AS, et al. Effect of Noninvasive Ventilation Delivered by Helmet
vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome: A
Randomized Clinical Trial. JAMA. 2016 Jun 14;315:2435-41.
13. Dr. Patrizia Pignatti, Allergy and Immunology Unit, Salvatore Maugeri Foundation,IRCCS, Pavia, Italy
Title: Towards a practical clinical use of fractioned exhaled nitric oxide levels in chronic cough
Comment on: Yi F, Chen R, Luo W, et al. Validity of Fractional Exhaled Nitric Oxide in Diagnosis of
Corticosteroid-Responsive Cough. Chest. 2016 Apr;149:1042-51.
14. Prof. Michele Carron, Department of Medicine, Anesthesiology and Intensive Care, University of Padova,
Padova, Italy
Title: A new horizon for the use of non-invasive ventilation in patients with acute respiratory distress syndrome
Comment on: Patel BK, Wolfe KS, Pohlman AS, et al. Effect of Noninvasive Ventilation Delivered by Helmet
vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome: A
Randomized Clinical Trial. JAMA. 2016 Jun 14;315:2435-41.
15. Dr. Padhraig S. Fleming, Barts and The London School of Medicine and Dentistry, Queen Mary University
of London, London, UK
Title: Evidence of spin in clinical trials in the surgical literature
Comment on: Arunachalam L, Hunter IA, Killeen S. Reporting of Randomized Controlled Trials With
Statistically Nonsignificant Primary Outcomes Published in High-Impact Surgical Journals. Ann Surg. 2016 Jun
1. [Epub ahead of print]
16. Dr. Karl O. Fagerstrom, Fagerstrom Consulting AB, Vaxholm, Sweden
Title: Abrupt versus gradual smoking cessation with pre-cessation nicotine replacement therapy for cigarette
smokers motivated to quit
Comment on: Lindson-Hawley N, Banting M, West R, et al. Gradual Versus Abrupt Smoking Cessation: A
Randomized, Controlled Noninferiority Trial. Ann Intern Med. 2016 May 3;164:585-92.
17. Dr. Po-Kuei Hsu, 1Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital;
2School of Medicine, National Yang-Ming University, Taipei, Taiwan
Title: The long-waited high level evidence in thoracic surgery
Comment on: Bendixen M, Jørgensen OD, Kronborg C, et al. Postoperative pain and quality of life after
lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a
randomised controlled trial. Lancet Oncol. 2016 Jun;17:836-44.

4. 18. Prof. Erkan Topkan, Department of Radiation Oncology, Baskent University Medical Faculty, Adana
Research and Treatment Center, Adana, Turkey
Title: Weight gain as a surrogate marker of longer survival in advanced non-small cell lung cancer patients
Comment on: Patel JD, Pereira JR, Chen J, et al. Relationship between efficacy outcomes and weight gain during
treatment of advanced,non-squamous,non-small-cell lung cancer patients.Ann Oncol. 2016 Aug;27:1612-9.
19. Dr. Jonathan P. Jarow, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver
Spring, MD, USA
Title: How much clinical evidence is enough: regulation of medical devices?
Comment on: Marcus HJ, Payne CJ, Hughes-Hallett A, et al. Regulatory approval of new medical devices: cross
sectional study.BMJ. 2016 May 20;353:i2587.
20. Dr. Annette McWilliams, 1Department of Respiratory Medicine, Fiona Stanley Hospital; 2University of
Western Australia; 3Thoracic Tumour Collaborative, WA Cancer and Palliative Care Network, Perth, Australia
Title: Does AQuIRE challenge the role of navigational bronchoscopy forperipheral pulmonary lesions?
Comment on: Ost DE, Ernst A, Lei X, et al; AQuIRE Bronchoscopy Registry. Diagnostic Yield and
Complications of Bronchoscopy for Peripheral Lung Lesions. Results of the AQuIRE Registry. Am J Respir Crit
Care Med. 2016 Jan 1;193:68-77.
21. Prof. José Leopoldo Ferreira Antunes, School of Public Health, University of São Paulo, São Paulo, Brazil
Title: The impact of unemployment on cancer mortality, and how to avoid it
Comment on: Maruthappu M, Watkins J, Noor AM, et al. Economic downturns,universal health coverage, and
cancer mortality in high-income and middle-income countries, 1990-2010: a longitudinal analysis. Lancet. 2016
Aug 13;388:684-95.
22. Dr. Antonio Rossi, Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy
Title: Immunotherapy in small-cell lung cancer: at what point are we?
Comment on: Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab
in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol.
2016 Jul;17:883-95.
23. Dr. Rajesh D. Shah, Department of Cardiothoracic Surgery, University Hospital of South ManchesterNHS
Foundation Trust, UK
Title: Is it time for SABR to overtake surgery as the treatment of choice for stage I non-small cell lung cancer?
Comment on: Paul S, Lee PC, Mao J, et al. Long term survival with stereotactic ablative radiotherapy (SABR)
versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity
matched comparative analysis.BMJ. 2016 Jul 8;354:i3570.
24. Dr. Daniel Morgensztern, Division of Medical Oncology, Washington University School of Medicine, St.
Louis, USA
Title: Immune checkpoint inhibition in patients with brain metastases

5. Comment on: Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-
small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2
trial. Lancet Oncol. 2016 Jul;17:976-83.
25. Dr. John Nemunaitis, Mary Crowley Cancer Research Center, Dallas, USA
Title: Tumor vaccines and cellular immunotherapies
Comment on: Dammeijer F, Lievense LA, Veerman GD, et al. Efficacy of Tumor Vaccines and Cellular
Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.J Clin Oncol. 2016
Sep 10;34:3204-12.
26. Dr. Neelesh Sharma, Department of Hematology/Oncology, University Hospitals Seidman Cancer Center,
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, USA
Title: Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old
question?
Comment on: Schuler M, Yang JC, Park K, et al; LUX-Lung 5 Investigators. Afatinib beyond progression in
patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III
randomized LUX-Lung 5 trial. Ann Oncol. 2016 Mar;27:417-23.
27. Prof. Sumithra J. Mandrekar, Department of Health Sciences Research, Mayo Clinic, Rochester, USA
Title: Time to progression ratio: promising new metric or just another metric?
Comment on: Cirkel GA, WeeberF, Bins S, et al. The time to progression ratio: a new individualized volumetric
parameter for the early detection of clinical benefit of targeted therapies.Ann Oncol. 2016 Aug;27:1638-43.
28. Prof. Michael J. Kelley, Medical Oncology, Department of Medicine, Duke University Medical Center,
Durham, USA
Title: Second line treatment of small cell lung cancer: more is better?
Comment on: Goto K, Ohe Y, Shibata T, et al; JCOG0605 investigators.Combined chemotherapy with cisplatin,
etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed
small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016
Aug;17:1147-57.
29. Dr. Giuseppe Giaccone, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown
University, Washington,USA
Title: Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design
Comment on: Papadimitrakopoulou V, Lee JJ, Wistuba II, et al. The BATTLE-2 Study: A Biomarker-Integrated
Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin
Oncol. 2016 Aug 1. [Epub ahead of print]
30. Dr. David E. Gerber, Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center,
The University of Texas Southwestern Medical Center, Dallas, USA
Title: Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based
therapies

6. Comment on: Papadimitrakopoulou V, Lee JJ, Wistuba II, et al. The BATTLE-2 Study: A Biomarker-Integrated
Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin
Oncol. 2016 Aug 1. [Epub ahead of print]
31. Prof. Sai Yendamuri, 1Department of Thoracic Surgery, Roswell Park Cancer Institute; 2Department of
Surgery, Jacobs School of Medicine and Biomedical Sciences, NY, USA
Title: Treatment of non-small cell lung cancer ≤2 cm in size: less may not be more
Comment on: Dai C, Shen J, Ren Y, et al. Choice of Surgical Procedure for Patients With Non-Small-Cell Lung
Cancer ≤ 1 cm or > 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based
Study. J Clin Oncol. 2016 Sep 10;34:3175-82.
32. Dr. Alvaro Gonzaleza, 1Clínica Universidad de Navarra, Laboratorio de Bioquímica; 2IdiSNA, Navarra
Institute for Health Research, Pamplona, Spain
Title: Are we ready to introduce T790M plasma analysis in the follow up of patients with NSCLC undertreatment
with EGFR-TKI?
Comment on: Oxnard GR, Thress KS, Alden RS, et al. Association Between Plasma Genotyping and Outcomes
of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct
1;34:3375-82.
33. Dr. Anne B. Chang, 1Department of Respiratory and Sleep Medicine, Queensland Children’s Hospital,
Brisbane, Qld University of Technology, South Brisbane; 2Child Health Division, Menzies School of Health
Research, Charles Darwin University, Darwin, Australia
Title: In search for the Holy Grail of cough guidelines
Comment on: Jiang M, Guan WJ, Fang ZF, et al. A Critical Review of the Quality of Cough Clinical Practice
Guidelines. Chest. 2016 Oct;150:777-788.
34. Prof. Sang-We Kim, Department of Oncology, Asan Medical Center, University of Ulsan College of
Medicine, Seoul, Korea
Title: Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung
cancer with activating epidermal growth factor receptor mutations
Comment on: Cheng Y, Murakami H, Yang PC, et al. Randomized Phase II Trial of Gefitinib With and Without
Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With
Activating Epidermal Growth Factor Receptor Mutations.J Clin Oncol. 2016 Sep 20;34:3258-66.
(On-going)
Prof. Elisabeth Quoix, Department of Chest Diseases, University Hospital of Strasbourg, Strasbourg,France
Comment on: Le Saux O, Falandry C, Gan HK, et al. Inclusion of elderly patients in oncology clinical trials. Ann
Oncol. 2016 Sep;27:1799-804.
Dr. Michele Milella, Regina Elena National Cancer Institute, Rome, Italy
Comment on: Cirkel GA, WeeberF, Bins S, et al. The time to progression ratio: a new individualized volumetric
parameter for the early detection of clinical benefit of targeted therapies.Ann Oncol. 2016 Aug;27:1638-43.

7. Prof. Nathan A. Berger, Center for Science, Health and Society, Case Western Reserve University School of
Medicine, Cleveland, USA
Comment on: Dossett LA, Hudson JN, Morris AM, et al. The primary care provider (PCP)-cancer specialist
relationship: A systematic review and mixed-methods meta-synthesis. CA Cancer J Clin. 2016 Oct 11. [Epub
ahead of print]
Dr. Jeffrey L. Jackson, Division of General Medicine, Zablocki VA Medical Center, Milwaukee, USA
Comment on: Bruce R, Chauvin A, Trinquart L, et al. Impact of interventions to improve the quality of peer
review of biomedical journals: a systematic review and meta-analysis. BMC Med. 2016 Jun 10;14:85.
Dr. Michael D. Shields, Queen's University Belfast & Consultant in Paediatric Respiratory Medicine, Royal
Belfast Hospital for Sick Children, Centre for Infection & Immunity, Queen's University Belfast, Belfast, UK
Comment on: Jiang M, Guan WJ, Fang ZF, et al. A Critical Review of the Quality of Cough Clinical Practice
Guidelines. Chest. 2016 Oct;150:777-788.
Prof. Nir Peled, Pulmonary Institute, Chaim Sheba Medical Centre, Tel Hashomer Thoracic Cancer Unit,
Davidoff Cancer Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel
Comment on: Walter JE, Heuvelmans MA, de Jong PA, et al. Occurrence and lung cancer probability of new
solid nodules at incidence screening with low-dose CT: analysis ofdata from the randomised, controlled NELSON
trial. Lancet Oncol. 2016 Jul;17:907-16.
Dr. Mauro Maniscalco, Section of Respiratory Medicine, Hospital S. Maria della Pietà, Naples, Italy
Comment on: Yi F, Chen R, Luo W, et al. Validity of Fractional Exhaled Nitric Oxide in Diagnosis of
Corticosteroid-Responsive Cough. Chest. 2016 Apr;149:1042-51.
Prof. Sue S. Yom, Department of Radiation Oncology, Helen Diller Family Comprehensive Cancer Center,
University of California, San Francisco, USA
Comment on: Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance
therapy or observation forpatients with oligometastatic non-small-cell lung cancer without progression after first-
line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec;17:1672-
1682.
Dr. Krishnansu S. Tewari, The Chao Family NCI-Designated Comprehensive Cancer Center, University of
California, Irvine Medical Center, Orange, USA
Comment on: Kim C, Prasad V. Strength of Validation for Surrogate End Points Used in the US Food and Drug
Administration's Approvalof Oncology Drugs. Mayo Clin Proc. 2016 May 10.
Dr. Kirby Lee, Department of Clinical Pharmacy, University of California, San Francisco, USA
Comment on: Dechartres A, Ravaud P, Atal I, et al. Association between trial registration and treatment effect
estimates: a meta-epidemiological study.BMC Med. 2016 Jul 4;14:100.
Dr. Winson Y. Cheung, British Columbia Cancer Agency,Vancouver, Canada

8. Comment on: Dossett LA, Hudson JN, Morris AM, et al. The primary care provider (PCP)-cancer specialist
relationship: A systematic review and mixed-methods meta-synthesis. CA Cancer J Clin. 2016 Oct 11. [Epub
ahead of print]
Dr. Richard T. Liu, Department ofPsychiatry and Human Behavior, Alpert Medical Schoolof Brown University,
Bradley Hospital, East Providence, USA
Comment on: Li S, Stampfer MJ, Williams DR, VanderWeele TJ. Association of Religious Service Attendance
With Mortality Among Women. JAMA Intern Med. 2016 Jun 1;176:777-85.
Dr. Lucio Crinò, Division of Medical Oncology, Azienda Ospedaliera S Maria della Misericordia, Perugia, Italy
Comment on: Schuler M, Yang JC, Park K, et al; LUX-Lung 5 Investigators. Afatinib beyond progression in
patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III
randomized LUX-Lung 5 trial. Ann Oncol. 2016 Mar;27:417-23.
Dr. Daniel L. Miller, Multidisciplinary Thoracic Oncology Program, WellStar Health System/Mayo Clinic Care
Network, Marietta, USA
Comment on: Walter JE, Heuvelmans MA, de Jong PA, et al. Occurrence and lung cancer probability of new
solid nodules at incidence screening with low-dose CT: analysis ofdata from the randomised, controlled NELSON
trial. Lancet Oncol. 2016 Jul;17:907-16.
Dr. Young Hak Kim, Department of Respiratory Medicine, Kyoto University Hospital, Kyoto, Japan
Comment on: Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance
therapy or observation forpatients with oligometastatic non-small-cell lung cancer without progression after first-
line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec;17:1672-
1682.
Prof. Liang Wang, Department of Biostatistics and Epidemiology, East Tennessee State University,Johnson City,
USA
Comment on: Xi B, Liang Y, Liu Y, et al. Tobacco use and second-hand smoke exposure in young adolescents
aged 12-15 years: data from 68 low-income and middle-income countries.Lancet Glob Health. 2016 Nov;4:e795-
e805.
Dr. Ross A. Soo, 1Department of Haematology-Oncology, National University Cancer Institute, National
University Health System; 2Cancer Science Institute of Singapore, National University of Singapore, Singapore;
3Department of Surgery, University of Western Australia, Perth, Australia
Comment on: Reck M, Rodríguez-Abreu D, Robinson AG, et al; KEYNOTE-024 Investigators.Pembrolizumab
versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375:1823-
1833.
Dr. Samuel J. Klempner, Department of Medicine, Division of Hematology-Oncology, Chao Family
Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, USA
Comment on: Gadgeel SM, Shaw AT, Govindan R, et al. Pooled Analysis ofCNS Response to Alectinib in Two
Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Dec;34:4079-
4085.

9. Prof. Leah L. Zullig, Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical
Center; Division of General Internal Medicine, Department of Medicine, Duke University, Durham, USA
Comment on: Pang HH, Wang X, Stinchcombe TE, et al. Enrollment Trends and Disparity Among Patients With
Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 Sep 19. [Epub ahead of print]